ZOTA Stock Overview
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India.
Zota Health Care Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹396.65|
|52 Week High||₹438.95|
|52 Week Low||₹136.65|
|1 Month Change||7.02%|
|3 Month Change||4.88%|
|1 Year Change||180.32%|
|3 Year Change||117.22%|
|5 Year Change||n/a|
|Change since IPO||277.63%|
Recent News & Updates
Zota Health Care (NSE:ZOTA) Has Re-Affirmed Its Dividend Of ₹1.00
Zota Health Care Limited's ( NSE:ZOTA ) investors are due to receive a payment of ₹1.00 per share on 30th of October...
Zota Health Care (NSE:ZOTA) Has Announced A Dividend Of ₹1.00
The board of Zota Health Care Limited ( NSE:ZOTA ) has announced that it will pay a dividend of ₹1.00 per share on the...
|ZOTA||IN Pharmaceuticals||IN Market|
Return vs Industry: ZOTA exceeded the Indian Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: ZOTA exceeded the Indian Market which returned 41.1% over the past year.
|ZOTA Average Weekly Movement||6.6%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||6.1%|
|10% most volatile stocks in IN Market||9.2%|
|10% least volatile stocks in IN Market||3.9%|
Stable Share Price: ZOTA is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ZOTA's weekly volatility (7%) has been stable over the past year.
About the Company
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India. It offers generic drugs, over-the-counter products, ayurvedic products, and nutraceutical products. The company provides various medicines for chronic illnesses, including heart disease, diabetes, thyroid, and others.
Zota Health Care Fundamentals Summary
|ZOTA fundamental statistics|
Is ZOTA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZOTA income statement (TTM)|
|Cost of Revenue||₹883.15m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.92|
|Net Profit Margin||3.72%|
How did ZOTA perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Is Zota Health Care undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZOTA (₹396.65) is trading below our estimate of fair value (₹601.41)
Significantly Below Fair Value: ZOTA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZOTA is poor value based on its PE Ratio (206.1x) compared to the Indian Pharmaceuticals industry average (22.5x).
PE vs Market: ZOTA is poor value based on its PE Ratio (206.1x) compared to the Indian market (18.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZOTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZOTA is overvalued based on its PB Ratio (11.1x) compared to the IN Pharmaceuticals industry average (2.8x).
How is Zota Health Care forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zota Health Care has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Zota Health Care performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZOTA has high quality earnings.
Growing Profit Margin: ZOTA's current net profit margins (3.7%) are higher than last year (2.8%).
Past Earnings Growth Analysis
Earnings Trend: ZOTA's earnings have declined by 30.2% per year over the past 5 years.
Accelerating Growth: ZOTA's earnings growth over the past year (85%) exceeds its 5-year average (-30.2% per year).
Earnings vs Industry: ZOTA earnings growth over the past year (85%) exceeded the Pharmaceuticals industry 29.2%.
Return on Equity
High ROE: ZOTA's Return on Equity (5.4%) is considered low.
How is Zota Health Care's financial position?
Financial Position Analysis
Short Term Liabilities: ZOTA's short term assets (₹831.8M) exceed its short term liabilities (₹304.0M).
Long Term Liabilities: ZOTA's short term assets (₹831.8M) exceed its long term liabilities (₹10.7M).
Debt to Equity History and Analysis
Debt Level: ZOTA is debt free.
Reducing Debt: ZOTA has no debt compared to 5 years ago when its debt to equity ratio was 13.1%.
Debt Coverage: ZOTA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ZOTA has no debt, therefore coverage of interest payments is not a concern.
What is Zota Health Care current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ZOTA's dividend (0.25%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: ZOTA's dividend (0.25%) is low compared to the top 25% of dividend payers in the Indian market (1.5%).
Stability and Growth of Payments
Stable Dividend: ZOTA has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: ZOTA has only been paying a dividend for 4 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (50.7%), ZOTA's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Moxesh Zota (31 yo)
Mr. Moxesh Ketanbhai Zota has been Managing Director and Director at Zota Health Care Limited since October 7, 2016. Mr. Zota is young entrepreneur with experience of 2 years in the industry and forays exp...
CEO Compensation Analysis
Compensation vs Market: Moxesh's total compensation ($USD34.43K) is about average for companies of similar size in the Indian market ($USD39.93K).
Compensation vs Earnings: Moxesh's compensation has been consistent with company performance over the past year.
Experienced Management: ZOTA's management team is seasoned and experienced (7.3 years average tenure).
Experienced Board: ZOTA's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ZOTA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Zota Health Care Limited's employee growth, exchange listings and data sources
- Name: Zota Health Care Limited
- Ticker: ZOTA
- Exchange: NSEI
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹9.980b
- Shares outstanding: 25.16m
- Website: https://www.zotahealthcare.com
Number of Employees
- Zota Health Care Limited
- Zota House
- 2/896, Hira Modi Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 16:14|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.